Advice

Following a full submission:

glycopyrronium inhalation powder (Seebri Breezhaler®) is accepted for use within NHS Scotland.

Indication under review: as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

In two phase III studies, glycopyrronium was statistically superior to placebo in improving lung function (forced expiratory volume in 1 second [FEV1]) after 12 weeks.

Download detailed advice138KB (PDF)

Download

Medicine details

Medicine name:
glycopyrronium (Seebri Breezhaler)
SMC ID:
829/12
Indication:
For a once daily maintenance bronchodilator treatment to relieve symptoms in patients with COPD.
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Respiratory system
Submission type
Full
Status
Accepted
Date advice published
14 January 2013